Upadacitinib beats placebo for psoriatic arthritis
A gender gap in negotiation emerges between boys and girls as early as age eight
1 April 2021Poorer and minority older adults are suspicious of the US health care system
1 April 2021Upadacitinib beats placebo for psoriatic arthritis
For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of the New England Journal of Medicine.
